News from cancernetwork.comFollowNews from cancernetwork.comSee all of cancernetwork.com news coverage in one place. Discover how cancernetwork.com’s media bias informs their coverage and compare with thousands of other news outlets.Ground News has come across 179 headlines reported on by cancernetwork.com during the past 3 months. Ground News rates cancernetwork.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.Follow See all of cancernetwork.com news coverage in one place. Discover how cancernetwork.com’s media bias informs their coverage and compare with thousands of other news outlets. Ground News has come across 179 headlines reported on by cancernetwork.com during the past 3 months. Ground News rates cancernetwork.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check. Information about cancernetwork.comWhere is cancernetwork.com located?cancernetwork.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top cancernetwork.com NewsEli Lilly · United StatesLilly gets traditional FDA approval for Retevmo for thyroid cancer (NYSE:LLY)100% Right coverage: 1 sourcesEli Lilly (LLY) has received traditional approval for its drug Retevmo for the treatment of medullary thyroid cancer with a RET mutation. Read more here.See the StoryAstraZeneca · United StatesFDA Expands Approval of Osimertinib in Lung Cancer100% Center coverage: 1 sourcesThe FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, theSee the StoryDARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myelomaDiscover how Johnson & Johnson's DARZALEX® therapies significantly improve multiple myeloma treatment outcomes. New data reveals increased efficacy and longer progression-free survival across patient populations.See the StoryLatest News StoriesTopics Most Covered by cancernetwork.comBreast CancerCancerFDAAstraZenecaOpinionBreast CancerCancerFDASources Covering Similar Topicsonclive.comtargetedonc.comcuretoday.comoncnursingnews.comPharmacy Timesonclive.comtargetedonc.comcuretoday.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to cancernetwork.comBreast CancerCalifornia, United StatesMarylandCancerUnited States